Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate
Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024
Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers
Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer
Zanidatamab Granted Priority Review for HER2-Positive Metastatic Biliary Tract Cancer
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review of the Biologics License Application (BLA) for zanidatamab, the human epidermal growth factor receptor 2 (HER2)-targeted bispecific antibody, for the treatment of previously treated, unresectable, locally advanced, or metastatic HER2-positive biliary […]
Introducing Pride in Biotech
We’re excited to launch Pride in Biotech, a Vancouver-based community to empower lesbian, gay, bisexual, transgender, and queer professionals in the drug development industry through networking, education, advocacy, professional development, and peer support. Brought to you by Zymeworks, the inaugural Pride in Biotech event is led by our ZYME&Proud team and will take place on […]
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks Provides Corporate Update and Reports First Quarter 2024 Financial Results
Zymeworks Announces Participation in Upcoming Investor Conferences
Zymeworks To Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
Zymeworks Presents New Data from Multiple Preclinical Development Programs at 2024 American Association for Cancer Research Annual Meeting
Zanidatamab Biologics License Application for Previously Treated HER2-Positive Metastatic Biliary Tract Cancer Completed
Zymeworks is pleased to announce, along with our partners Jazz Pharmaceuticals, completion of the rolling submission of a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) seeking accelerated approval for the HER2-targeted bispecific antibody zanidatamab as a treatment for previously-treated, unresectable, locally advanced, or metastatic HER2-positive biliary tract cancer (BTC). If […]
